within Pharmacolibrary.Drugs.ATC.B;

model B01AC25_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.7083333333333334,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cangrelor is a potent, reversible, intravenous P2Y12 platelet inhibitor used to prevent thrombotic events in patients undergoing percutaneous coronary intervention (PCI). It is approved for use in adults in the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported in patients with coronary artery disease undergoing PCI, receiving weight-adjusted IV bolus and infusion.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2121702&quot;>10.1080/17512433.2022.2121702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36065676/&quot;>https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>Bhattad, VB, et al., &amp; Khouzam, RN (2019). Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. <i>Annals of translational medicine</i> 7(17) 408–None. DOI:<a href=&quot;https://doi.org/10.21037/atm.2019.07.64&quot;>10.21037/atm.2019.07.64</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31660307/&quot;>https://pubmed.ncbi.nlm.nih.gov/31660307</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC25_1;
